The Group weathered the challenges of the first half well and is on track to accelerate revenues in the second half as supply constraints ease and our marketing and product development initiatives drive increased demand. We remain on track to meet market expectations for full-year financial performance, noting that the timing of some orders in the fourth quarter depends on the rate of recovery in these markets.
OPERATIONAL AND FINANCIAL HIGHLIGHTS
H1 revenue growth impacted by lockdown in
Solid performance of prescription drugs with revenues of
Free cash flow of
DEVELOP OUR BUSINESS
Integration of ScarAway and U.S. rights to Kelo-cote completed, with revenue in line with expectations
Last marketing authorizations for Nizoral transferred from J&J to Alliance in
Several new complementary exclusive products have been launched or are expected to be launched this year, including Kelo-cote Kids and Kelo-cote Scar Sheets in
The ERP system has been successfully deployed in other territories, including
Scope 1 and 2 emissions target set to reach net zero by 2030, with an interim reduction of 65% by 2025
Commenting on the results,
“The second half of 2022 has gotten off to an encouraging start as blockages and supply constraints have eased. We expect strong sales growth in the second half as our marketing campaigns return profits, we integrate our new distribution partners and launch new products to increase our market share. Our guidance for FY22 includes several orders from large retailers in the fourth quarter to meet increased demand, with the timing of these orders dependent on the rate of recovery in these markets. Our core business remains strong with new product launches expected in 2023 to ensure future growth.
The Group’s performance is assessed using Alternative Performance Measures (“APMs”), which are measures that are not defined by IFRS but are used by management to monitor the ongoing performance of the business by against shorter-term budgets and forecasts and longer-term strategic objectives of the Group. plans. IAPs are defined in note 17.
Tel: + 44 (0)1249 466966
We are primarily focused on marketing consumer healthcare brands, supplemented by a smaller prescription drug business. In total, we own the marketing rights to approximately 80 brands, with revenue generated through a mix of direct sales, distributors and e-commerce.
Based in the